Latest Commercialization News

Firebird Metals is developing Lithium Manganese Rich cathode materials to target next-generation solid-state batteries, aiming to strengthen its position in the evolving EV and high-energy battery markets.

Acrux Limited reports promising revenue growth driven by new topical generic launches in the US and secures crucial RDTI funding, marking a strategic shift under new CEO John Warmbrunn.

Ionic Rare Earths’ Belfast plant is ramping up production of critical heavy rare earth oxides to meet soaring demand from Western markets following China’s export restrictions. This strategic move positions the company as a key supplier for defence, renewables, and advanced manufacturing sectors.

Great Northern Minerals advances the sale of a majority stake in Golden Ant Mining, securing a $1 million payment upon final phase completion, while maintaining a $1.29 million cash balance and exploring new resource opportunities.

Findi Limited has completed a successful pilot of its BC Max Centres with Central Bank of India and launched a national rollout starting with 76 locations, aiming to transform digital banking access across India.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.

Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.

Aeeris Ltd reported a strong Q4 FY25 with a 13.3% increase in annual recurring revenue, driven by the full deployment of its proprietary AWARE system and strategic in-house service transitions.

Jade Gas Holdings has secured a A$3.64 million director loan to advance production at its Red Lake Gas Field, anticipating a transformational gas breakthrough this quarter.

BrainChip Holdings reported a solid June quarter with $13.5 million in cash, increased customer inflows, and a strategic decision to remain listed on the ASX. The company advanced multiple commercial collaborations and expanded its intellectual property portfolio, signaling confidence in its edge AI technology roadmap.

Avecho Biotechnology has ramped up recruitment in its pivotal Phase III insomnia trial and is advancing plans for regulatory approval and commercialization of its TPM®-enhanced CBD capsule, aiming to be the first over-the-counter CBD insomnia treatment in Australia.

Scalare Partners has forged a strategic collaboration with Silicon Catalyst, a leading US semiconductor accelerator, while advancing its acquisition of Tank Stream Labs, a premier Australian tech coworking provider. These moves position Scalare at the forefront of deep tech support and infrastructure expansion.